Results 211 to 220 of about 489,898 (256)

Emerging threat of avian influenza to the world's vultures

Conservation Biology, EarlyView.
Jon Morant, Andrea Santangeli, Pablo Plaza, Sergio A. Lambertucci   +3 more
wiley   +1 more source

Engineering Antibody Evolution: Germline‐Targeting HIV Vaccines Reach a Turning Point

Immunology &Cell Biology, EarlyView.
This commentary examines three recent Nature studies demonstrating a conceptual shift in HIV vaccine design, demonstrating how germline‐targeting HIV vaccines can progress beyond expanding rare broad neutralizing antibody (bnAb) precursors to deliberately guiding their affinity maturation into bnAbs in non‐human primates.
Rowena A. Bull, Deborah L. Burnett
wiley   +1 more source

Potential to Avert Additional Influenza Burden in the United States with Use of Adjuvanted vs. Standard Influenza Vaccines in Individuals 50-64 Years of Age. [PDF]

Vaccines (Basel)
McGovern I, Flores R, Haag MDM.
europepmc   +1 more source

Would patients over 65 years of age accept vaccination while hospitalised? An assessment of eligibility and acceptability

Internal Medicine Journal, EarlyView.
Abstract Background Vaccination is effective at preventing severe illness related to influenza, pneumococcal disease and coronavirus disease 2019 COVID‐19. Vaccine coverage among older Australians is incomplete, and hospitals currently administer very few vaccine doses.
Victoria Deacon, Kristen Overton, Parthsinh Solanki, Ethan MacMinn, Anthea L. Katelaris, Jeffrey J. Post   +5 more
wiley   +1 more source

Safety and heterogeneity of mRNA-based seasonal Influenza vaccines: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Saudi Med
Albargy HA, Othman AA.
europepmc   +1 more source

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

Internal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard, Michael Barnett, Heidi Beadnall, Mirasol Forcadela, Lesley‐Ann Hall, Victoria G. Hall, Todd Hardy, Danny Hsu, Paul Kinsella, Mastura Monif, Sudarshini Ramanathan, Stephen W. Reddel, Sean Riminton, Douglas F. Johnson   +13 more
wiley   +1 more source

A Phase 1/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults. [PDF]

Clin Infect Dis
Cosgrove CA, Avanesov A, Rust D, Osibajo S, Kang K, Leav B, ODYSSEY Study Group .   +6 more
europepmc   +1 more source

Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement

Internal Medicine Journal, EarlyView.
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley, Philip George, Gemma Reynolds, Adam Stewart, Hang Quach, Nicole O'Leary, Zoe McQuilten, Andrea S. Henden, Lynette Chee, Chan Y. Cheah, Olivia Bupha‐Intr, Emily Blyth, Ben Teh, Monica Slavin, Michael Dickinson, Robert Weinkove   +15 more
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Cross-reactivity between antibodies induced by European swine influenza vaccines and Spanish swine influenza strains. [PDF]

Front Vet Sci
Encinas P, Nogales A, Nelson MI, García-Sastre A, Del Real G.   +4 more
europepmc   +1 more source